- Home
- TSI vs GOSS Comparison
TSI vs GOSS Comparison
Compare TSI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | GOSS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 88.6M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TSI | GOSS |
|---|---|---|
| Price | $4.53 | $0.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 107.3K | ★ 10.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.43 | $0.16 |
| 52 Week High | $5.06 | $3.87 |
Technical Indicators
Market Signals| Indicator | TSI | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 32.18 |
| Support Level | $4.43 | $0.16 |
| Resistance Level | $4.63 | $0.36 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 25.00 | 31.32 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).